Literature DB >> 10468687

One-year follow-up of newly diagnosed irritable bowel syndrome patients.

A Ruigómez1, M A Wallander, S Johansson, L A García Rodríguez.   

Abstract

BACKGROUND: Irritable bowel syndrome is the most common functional gastrointestinal disorder seen by general physicians.
METHODS: We followed up a population-based cohort of newly diagnosed irritable bowel syndrome patients aged 20-79 years, to examine patterns of treatment, comorbidity and healthcare utilization. We used the UK General Practice Research Database as the source population. Individuals with other gastrointestinal diseases, cancer and pregnant women were not included. There were 2956 patients in our final cohort.
RESULTS: Irritable bowel syndrome patients were mainly young and middle-aged; only 12% were 60 years or older. The majority of patients were women (74%). There were no marked differences in terms of use of healthcare services or comorbidity status in the year before irritable bowel syndrome diagnosis as compared to the year after. Fourteen per cent of irritable bowel syndrome patients received no drug treatment at all. Among those treated, the first choice was an antispasmodic. Elderly patients (>60 years old) were more likely to receive drug treatment. Females had a slightly higher probability of being treated than men, except for the category of anti-diarrhoeal drugs.
CONCLUSION: This study has shown that irritable bowel syndrome patients are mainly young and female. We also found that treatment pattern varied according to age and gender. Elderly patients and females were at a higher risk of receiving drug treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10468687     DOI: 10.1046/j.1365-2036.1999.00576.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Could gastrointestinal disorders differ in two close but divergent social environments?

Authors:  Ewa Grodzinsky; Claes Hallert; Tomas Faresjö; Elisabet Bergfors; Ashild Olsen Faresjö
Journal:  Int J Health Geogr       Date:  2012-02-06       Impact factor: 3.918

Review 2.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 3.  Irritable bowel syndrome and chronic pelvic pain: a singular or two different clinical syndrome?

Authors:  Anna Matheis; Ute Martens; Johannes Kruse; Paul Enck
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

4.  Hyperimmune egg powder for the treatment of irritable bowel syndrome: A case series.

Authors:  Mark W Morningstar
Journal:  J Chiropr Med       Date:  2004

5.  Irritable bowel syndrome and gastroesophageal reflux disease in primary care: is there a link?

Authors:  Ana Ruigómez; Mari-Ann Wallander; Saga Johansson; Luis Alberto García Rodríguez
Journal:  Dig Dis Sci       Date:  2008-08-22       Impact factor: 3.199

6.  Irritable bowel syndrome in adults over 35 years in Shiraz, southern Iran: prevalence and associated factors.

Authors:  Farnaz Khademolhosseini; Davood Mehrabani; Marzieh Nejabat; Mahmood Beheshti; Seyed Taghi Heydari; Alireza Mirahmadizadeh; Moosa Salehi; Najaf Zare; Mehdi Saberi-Firoozi
Journal:  J Res Med Sci       Date:  2011-02       Impact factor: 1.852

7.  Psychological illness is commonly associated with functional gastrointestinal disorders and is important to consider during patient consultation: a population-based study.

Authors:  Ture Alander; Kurt Svärdsudd; Sven-Erik Johansson; Lars Agréus
Journal:  BMC Med       Date:  2005-05-13       Impact factor: 8.775

8.  Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: a randomized double-blind placebo-controlled study.

Authors:  Ramesh R Rai; Manisha Dwivedi; Nirmal Kumar
Journal:  Saudi J Gastroenterol       Date:  2014 Nov-Dec       Impact factor: 2.485

9.  Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial.

Authors:  C J Bijkerk; N J de Wit; J W M Muris; P J Whorwell; J A Knottnerus; A W Hoes
Journal:  BMJ       Date:  2009-08-27

10.  Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome.

Authors:  Xing-Cun Xue; Xiao-Xia Qi; Xiao-Yan Wan
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.